CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Peter R Smith who wrote ()	7/8/1996 4:48:00 PM
From: Brett Koplin	of 675

I also agree it is still a buy. I thought long and hard about the cerestat trial for stroke. this is a novel drug and blocks NMDA receptors- the tough thing about developing such a drug is a side effect is that it can cause psychosis-however this drug is well tolerated.The preliminary data looks good-some question of statistical significance but one thing that was very telling was that the clinicians could tell which was the cerestat and placebo before the code was broken. Such drugs have a big market, as you may know TPA was approved for treatment of stroke-although i'm not a neurologist there is a fairly small window of time for using this and a lot of contra-indications. Brett Koplin rochester Mn.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext